Clinical trials: Decompensated Cirrhosis
Decompensated Cirrhosis
Risk Stratification for Adverse Events in End-Stage Liver Disease
Study Goal The goal of this multicenter, prospective observational cohort study is to develop and validate a multimodal predictive model that integrates portal hypertension, inflammation, and liver function indicators to predict…
- Trial name
- D-TECT (NCT07880678)
- Testing
- Routine Clinical Care with Biospecimen Collection and Free MRE Testing
- Volunteers
- 2,235 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Decompensated Cirrhosis
To Develop and Validate an Equation for Determination of Major Adverse Kidney Events in Patients With Decompensated Cirrhosis and Ascites.
Acute kidney injury (AKI) is the sudden loss of kidney function that occurs frequently in hospitalised patients with cirrhosis. It develops in up to 53% and is independently associated with high short-term mortality.
- Trial name
- NCT07794787
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Decompensated Cirrhosis of Liver
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from…
- Conditions
- Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)
- Trial name
- COMBAT (NCT05895136)
- Testing
- Human albumin, Enoxaparin, Standard medical treatment
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 90 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Cirrhoses, Liver, Decompensated Cirrhosis of Liver
Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver
Cirrhosis, a leading cause of global mortality, progresses to life-threatening complications like ascites, hepatic encephalopathy, and hepatorenal syndrome.
- Trial name
- NCT07800598
- Testing
- Allopurinol Tablet
- Where
- 2 sites in Bangladesh
- Volunteers
- 54 people
- Sponsor
- Bangladesh Medical University
Acute Kidney Injury, Cirrhosis
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital.
- Conditions
- Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
- Trial name
- DROP-AKI (NCT06937307)
- Testing
- Droxidopa capsules
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Giuseppe Cullaro, MD
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Training and Validation Data Collection Study
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD TVDCS (NCT06675604)
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Cirrhosis
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated…
- Trial name
- LiverGut (NCT06533852)
- Testing
- Fecal Microbiome Transplantation (FMT)
- Where
- 8 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Decompensated Cirrhosis, Bacterial Infections
Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)
Study to comparing conventrional antibiotic strategies versus regimens guided by epidemiological surveillance in infected patients with cirrhosis.
- Trial name
- SURVIC (NCT05783661)
- Testing
- Conventional antibiotic strategies, Regimens guided by epidemiological surveillance
- Where
- Spain
- Volunteers
- 198 people
- Sponsor
- Eva Bonfill
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and…
- Trial name
- CirrhoCare (NCT06223893)
- Testing
- CirrhoCare management system
- Where
- 15 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University College, London
Decompensated Cirrhosis
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
Three sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg).
- Trial name
- HCL001 (NCT07488546)
- Testing
- Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Huicun Medical Technology Co., Ltd.
Decompensated Cirrhosis, Liver Transplantation
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
The MELD score is a predictive model of cirrhosis mortality used in France since 2007 to prioritize access to liver transplantation for patients enrolled in the national waiting list.
- Trial name
- SUPERMELD (NCT03820271)
- Testing
- SuperMELD
- Where
- France
- Volunteers
- 501 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Cirrhosis of Liver
Using Telemedicine to Assist in the Clinical Care of Patients With Decompensated Cirrhosis
The goal of this clinical trial is to learn if an integrated digital and telemedicine care model works to manage decompensated cirrhosis in patients.
- Trial name
- NCT07439770
- Testing
- Telemedicine care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Decompensated Liver Cirrhosis, Cirrhosis
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion.
- Conditions
- Decompensated Liver Cirrhosis, Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Cirrhosis and Ascites
- Trial name
- NCT06764966
- Testing
- Atorvastatin 20 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- CAMC Health System
Decompensated Hepatitis B Cirrhosis
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis
Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis…
- Trial name
- HBV-DC (NCT07413549)
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Beijing Tuohua Weiye Biotechnology Co., Ltd.
Decompensated Cirrhosis and Ascites
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
The goal of this clinical biomarker validation trial is to test the effect of a predictive biomarker panel to human albumin infusions in patients with liver cirrhosis and ascites.
- Trial name
- NCT05056220
- Testing
- Human albumin, sodium chloride
- Where
- 12 sites in Belgium, Denmark and 5 more
- Volunteers
- 240 people
- Sponsor
- Aleksander Krag